Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients

Transplant Proc. 2001 Aug;33(5):2767-9. doi: 10.1016/s0041-1345(01)02184-4.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Basiliximab
  • Comorbidity
  • Daclizumab
  • Diabetes Mellitus / epidemiology
  • Female
  • Follow-Up Studies
  • Graft Rejection / prevention & control
  • Histocompatibility Testing
  • Humans
  • Hypertension / complications
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use*
  • Immunosuppression Therapy / methods
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Isoantibodies / blood
  • Kidney Transplantation / immunology*
  • Middle Aged
  • Myocardial Ischemia / complications
  • Recombinant Fusion Proteins*
  • Safety
  • Time Factors
  • Transplantation, Homologous

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Isoantibodies
  • Recombinant Fusion Proteins
  • Basiliximab
  • Daclizumab